Product/Composition:- | Vildagliptin + Metformin Tablets |
---|---|
Strength:- | Vildagliptin 50 mg + Metformin 500 mg/850mg/1000mg |
Form:- | Tablets |
Reference Brands:- | Galvus Met (EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Vildagliptin inhibits DPP-4, increasing incretin hormones (GLP-1, GIP) to boost insulin secretion and suppress glucagon. Metformin reduces hepatic glucose output and improves insulin sensitivity. Together, they offer synergistic glucose control, reduced HbA1c, and a lower risk of hypoglycemia or weight gain. Ideal for managing type 2 diabetes with dual action.
Vildagliptin and Metformin combination tablets are approved in the European Union under brand names like Galvus Met, Eucreas, and Icandra. These are indicated for the treatment of type 2 diabetes mellitus in adults when diet, exercise, and monotherapy do not provide adequate glycemic control. The product is regulated by the European Medicines Agency (EMA) and follows strict pharmacovigilance and quality standards. As of now, no FDA approval exists for Vildagliptin in the USA, limiting its availability. Manufacturers must comply with EU GMP standards and labeling requirements. Pharmatradz.com facilitates sourcing EU-approved diabetic formulations globally.